Cargando…
Durable Response to Venetoclax Monotherapy in Richter’s Syndrome: A Case Report and Review of Literature
In 2017, 20,110 people in the United States were diagnosed with chronic lymphocytic leukemia (CLL). Of these patients, 5-15% will ultimately undergo Richter’s syndrome (RS), a transformation to a more aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL) type. Particularly when th...
Autores principales: | Kollipara, Revathi, Szymanski, Kelly, Mahon, Brett, Venugopal, Parameswaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153679/ https://www.ncbi.nlm.nih.gov/pubmed/32300445 http://dx.doi.org/10.14740/jh473 |
Ejemplares similares
-
An experience with ibrutinib monotherapy for Richter’s syndrome isolated in the central nervous system
por: Nato, Yuma, et al.
Publicado: (2022) -
Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter’s syndrome
por: Tutaeva, Victoria Vladimirovna, et al.
Publicado: (2022) -
Richter Syndrome
por: Condoluci, Adalgisa, et al.
Publicado: (2021) -
Correction to: Long-term effect of venetoclax therapy in a patient with the transformation of chronic lymphocytic leukemia into Richter’s syndrome
Publicado: (2023) -
Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)